These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32879337)

  • 1. Phosphoproteomic analysis of dengue virus infected U937 cells and identification of pyruvate kinase M2 as a differentially phosphorylated phosphoprotein.
    Wongtrakul J; Thongtan T; Pannengpetch S; Wikan N; Kantamala D; Kumrapich B; Suwan W; Smith DR
    Sci Rep; 2020 Sep; 10(1):14493. PubMed ID: 32879337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Disulfide Isomerase Inhibitor Suppresses Viral Replication and Production during Antibody-Dependent Enhancement of Dengue Virus Infection in Human Monocytic Cells.
    Rawarak N; Suttitheptumrong A; Reamtong O; Boonnak K; Pattanakitsakul SN
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan.
    Piccini LE; Carro AC; Quintana VM; Damonte EB
    Virus Res; 2020 Dec; 290():198150. PubMed ID: 32866533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection.
    Chan CYY; Low JZH; Gan ES; Ong EZ; Zhang SL; Tan HC; Chai X; Ghosh S; Ooi EE; Chan KR
    mSphere; 2019 Sep; 4(5):. PubMed ID: 31533998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infection of epithelial cells with dengue virus promotes the expression of proteins favoring the replication of certain viral strains.
    Martínez-Betancur V; Marín-Villa M; Martínez-Gutierrez M
    J Med Virol; 2014 Aug; 86(8):1448-58. PubMed ID: 24374781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytokine response of U937-derived macrophages infected through antibody-dependent enhancement of dengue virus disrupts cell apical-junction complexes and increases vascular permeability.
    Puerta-Guardo H; Raya-Sandino A; González-Mariscal L; Rosales VH; Ayala-Dávila J; Chávez-Mungía B; Martínez-Fong D; Medina F; Ludert JE; del Angel RM
    J Virol; 2013 Jul; 87(13):7486-501. PubMed ID: 23616663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RPLP1 and RPLP2 Are Essential Flavivirus Host Factors That Promote Early Viral Protein Accumulation.
    Campos RK; Wong B; Xie X; Lu YF; Shi PY; Pompon J; Garcia-Blanco MA; Bradrick SS
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27974556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Autophagy-Mediated Dengue Virus Antibody-Dependent Enhancement Infection of THP-1 Cells.
    Jiang L; Sun Q
    Intervirology; 2020; 63(1-6):57-65. PubMed ID: 33202415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains.
    Puerta-Guardo H; Mosso C; Medina F; Liprandi F; Ludert JE; del Angel RM
    J Gen Virol; 2010 Feb; 91(Pt 2):394-403. PubMed ID: 19828759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative.
    Ayala-Nuñez NV; Jarupathirun P; Kaptein SJ; Neyts J; Smit JM
    Antiviral Res; 2013 Oct; 100(1):238-45. PubMed ID: 23994499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
    Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
    J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.
    Fowler AM; Tang WW; Young MP; Mamidi A; Viramontes KM; McCauley MD; Carlin AF; Schooley RT; Swanstrom J; Baric RS; Govero J; Diamond MS; Shresta S
    Cell Host Microbe; 2018 Nov; 24(5):743-750.e5. PubMed ID: 30439343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells.
    Chareonsirisuthigul T; Kalayanarooj S; Ubol S
    J Gen Virol; 2007 Feb; 88(Pt 2):365-375. PubMed ID: 17251552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.
    Wang Y; Si L; Luo Y; Guo X; Zhou J; Fang D; Yan H; Zeng G; Jiang L
    Appl Microbiol Biotechnol; 2015 Nov; 99(22):9685-98. PubMed ID: 26219500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells.
    Asad S; Feitosa-Suntheimer F; Gold A; Londono-Renteria B; Colpitts TM
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30735189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
    Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
    Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.